Ausgabe 2/2024
Inhalt (8 Artikel)
Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations
Chukwunonso K. Nwabufo
Prediction of ROS1 and TRKA/B/C occupancy in plasma and cerebrospinal fluid for entrectinib alone and in DDIs using physiologically based pharmacokinetic (PBPK) modeling approach
Liangang Chen, Na Yao, Hongjie Yang, Shaofeng Zhang, Kai Zhang
Genetic polymorphisms as predictive biomarkers of adverse events during preoperative chemotherapy in esophageal cancer
Yao Liang, Osamu Maeda, Kazushi Miyata, Mitsuro Kanda, Shizuki Sugita, Dai Shimizu, Kazuki Nishida, Yasuhiro Kodera, Yuichi Ando
Are novel oral oncolytics underdosed in obese patients?
Lishi Lin, Ellen K. O. van der Meer, Neeltje Steeghs, Jos H. Beijnen, Alwin D. R. Huitema
The combination of brentuximab vedotin and chidamide synergistically suppresses the proliferation of T-cell lymphoma cells through the enhancement of apoptosis
Yukio Tonozuka, Hiroshi Tanaka, Kazumi Nomura, Kazuya Sakaguchi, Junpei Soeda, Yoshihide Kakimoto
Association between chemotherapy-induced myelosuppression and curative efficacy of 2-cycle chemotherapy in small cell lung cancer
Xinyu Wang, Shujun Gu, Jingli Wen, Lixi Zhang, Xu Qi
Removal rate of 5-fluorouracil and its metabolites in patients on hemodialysis: a report of two cases of colorectal cancer patients with end-stage renal failure
Hirotaka Imamaki, Mitsuaki Oura, Fumiya Oguro, Yoshitaka Nishikawa, Shunsaku Nakagawa, Taro Funakoshi, Shigeki Kataoka, Takahiro Horimatsu, Atsushi Yonezawa, Takeshi Matsubara, Norihiko Watanabe, Manabu Muto, Motoko Yanagita, Yoshinao Ozaki
Pazopanib pharmacokinetically guided dose optimization in three cancer patients with gastrointestinal resection
Cléa Tardy, Alicja Puszkiel, Pascaline Boudou-Rouquette, Sixtine De Percin, Jérôme Alexandre, Marion Berge, Guillaume Ulmann, Benoit Blanchet, Rui Batista, Francois Goldwasser, Audrey Thomas Schoemann